drugset / Trial / NCT00174408

Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

NCT00174408

Phase 3 Completed 110 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)

Timeline

Start
1990-03
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic

Indications

No indication recorded.